Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | MT-5111: immunotoxin in HER2+ solid tumours

Zev Wainberg • 8 Jul 2020
ESMO WCGIC 2020
Gastrointestinal Cancer General MT-5111

Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, outlines results from a Phase I study evaluating MT-5111, a novel immunotoxin, in HER-2 positive solid tumours. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Zev Wainberg

0:43
daNIS-2: NIS793 with nab-paclitaxel and gemcitabine in mPDAC
Zev Wainberg • 20 Jan 2023
0:32
DKN-01 with bevacizumab and chemotherapy in advanced CRC
Zev Wainberg • 20 Jan 2023
0:54
NAPOLI-3: first-line NALIRIFOX in metastatic pancreatic ductal adenocarcinoma
Zev Wainberg • 20 Jan 2023
0:48
Current and future directions in gastric cancer research
Zev Wainberg • 12 Apr 2022

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals